๐Ÿ“Š This is a company profile preview from Tablestat.com Request a Free Trial Now

Company profile: Tharimmune

1.1 - Company Overview

Tharimmune Logo

Tharimmune

Headquarter: United Kingdom
Founded: 20XX๐Ÿ”’
Employees: 100-500๐Ÿ”’
๐ŸŒ Website

Company description

  • Provider of development-stage therapeutics for cancer and chronic pruritus, including TH104, a transmucosal buccal film with nalmefene targeting ยต- and kappa-opioid receptors and inhibiting IL-17 for pruritus in PBC and other conditions; TH3215, a bispecific HER2/HER3 antibody; and TH1940, an anti-PD-1 Picobody therapy.

Products and services

  • TH104: A proprietary transmucosal buccal film embedded with nalmefene that targets ยต- and ฮบ-opioid receptors and inhibits IL-17 expression to treat chronic pruritus in PBC and related conditions
  • TH1940: An anti-PD-1 therapy utilizing Picobodies with greater binding affinity to novel epitopes, aiming to improve cancer treatment outcomes by more effective checkpoint inhibition
  • TH3215: A bispecific antibody targeting HER2 and HER3 that binds unique epitopes to potentially modulate tumor cell signaling for oncology applications

Key contacts

๐Ÿ”’
๐Ÿ”’

Financial details

๐Ÿ”’

1.2 - Competitors and similar companies to Tharimmune

Normunity Logo

Normunity

HQ: United States Website
  • Description: Provider of precision immuno-oncology medicines focused on immune normalizersโ€”novel cancer immunotherapies that restore normal immune responses. Includes the Chen Lab Discovery Platform to identify and validate novel targets and Normunity Drug Development to create monoclonal antibodies based on these discoveries.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: โ—โ—โ—โ—โ—
  • Total funding raised: $โ—โ—โ—m
  • Backers: โ—โ—โ—โ—โ—โ—โ—โ—โ—โ—
  • Acquisitions: โ—โ—
View full Normunity company profile โ†’
Cellerant Therapeutics Logo

Cellerant Therapeutics

HQ: United States Website
  • Description: Provider of clinical-stage cell- and antibody-based immunotherapies.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: โ—โ—โ—โ—โ—
  • Total funding raised: $โ—โ—โ—m
  • Backers: โ—โ—โ—โ—โ—โ—โ—โ—โ—โ—
  • Acquisitions: โ—โ—
View full Cellerant Therapeutics company profile โ†’
Mobidiag Logo

Mobidiag

HQ: Finland Website
  • Description: Provider of molecular diagnostic solutions for the detection of infectious diseases, including gastrointestinal infections, antimicrobial resistance management, healthcare-associated infections (HAIs), respiratory infections and sepsis, based on well-established qPCR and microarray technologies.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: โ—โ—โ—โ—โ—
  • Total funding raised: $โ—โ—โ—m
  • Backers: โ—โ—โ—โ—โ—โ—โ—โ—โ—โ—
  • Acquisitions: โ—โ—
View full Mobidiag company profile โ†’
GPC Biotech Logo

GPC Biotech

HQ: Germany Website
  • Description: Provider of anticancer drug discovery and development as a German biopharmaceutical company. Portfolio includes Satraplatin, a platinum-based small molecule for prostate cancer; MAb 1D09C3, a monoclonal antibody for lymphoma; and RGB-286199, a small molecule for refractory cancer.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: โ—โ—โ—โ—โ—
  • Total funding raised: $โ—โ—โ—m
  • Backers: โ—โ—โ—โ—โ—โ—โ—โ—โ—โ—
  • Acquisitions: โ—โ—
View full GPC Biotech company profile โ†’
Synimmune Logo

Synimmune

HQ: Germany Website
  • Description: Provider of innovative mono- and bispecific anti-tumor antibodies for treating life-threatening diseases, focusing on orphan hematopoietic malignancies; lead product candidate is the antibody FLYSYN.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: โ—โ—โ—โ—โ—
  • Total funding raised: $โ—โ—โ—m
  • Backers: โ—โ—โ—โ—โ—โ—โ—โ—โ—โ—
  • Acquisitions: โ—โ—
View full Synimmune company profile โ†’
๐Ÿ”’

2.M&A buyers

2.1 Potential strategic acquirers in the sector

๐Ÿ”’
๐Ÿ”’
๐Ÿ”’
๐Ÿ”’ View all strategic buyers with complete profiles
Start Free Trial โ†’

2.2 - Strategic buyer groups for Tharimmune

๐Ÿ”’

Buyer group 1: โ–ˆโ–ˆโ–ˆโ–ˆโ–ˆโ–ˆโ–ˆโ–ˆ โ–ˆโ–ˆโ–ˆโ–ˆโ–ˆโ–ˆโ–ˆโ–ˆ

โ—โ— companies
Description: โ–ˆโ–ˆโ–ˆโ–ˆโ–ˆโ–ˆโ–ˆโ–ˆ โ–ˆโ–ˆโ–ˆโ–ˆโ–ˆโ–ˆโ–ˆโ–ˆ โ–ˆโ–ˆโ–ˆโ–ˆโ–ˆโ–ˆโ–ˆโ–ˆ โ–ˆโ–ˆโ–ˆโ–ˆโ–ˆโ–ˆโ–ˆโ–ˆ โ–ˆโ–ˆโ–ˆโ–ˆโ–ˆโ–ˆโ–ˆโ–ˆ โ–ˆโ–ˆโ–ˆโ–ˆโ–ˆโ–ˆโ–ˆโ–ˆ โ–ˆโ–ˆโ–ˆโ–ˆโ–ˆโ–ˆโ–ˆโ–ˆ โ–ˆโ–ˆโ–ˆโ–ˆโ–ˆโ–ˆโ–ˆโ–ˆ โ–ˆโ–ˆโ–ˆโ–ˆโ–ˆโ–ˆโ–ˆโ–ˆ โ–ˆโ–ˆโ–ˆโ–ˆโ–ˆโ–ˆโ–ˆโ–ˆ
Key Products: โ–ˆโ–ˆโ–ˆโ–ˆโ–ˆโ–ˆโ–ˆโ–ˆ, โ–ˆโ–ˆโ–ˆโ–ˆโ–ˆโ–ˆโ–ˆโ–ˆ, โ–ˆโ–ˆโ–ˆโ–ˆโ–ˆโ–ˆโ–ˆโ–ˆ, โ–ˆโ–ˆโ–ˆโ–ˆโ–ˆโ–ˆโ–ˆโ–ˆ
๐Ÿ”’ View all companies in this group
Request Free Trial Now โ†’
๐Ÿ”’

Buyer group 2: โ–ˆโ–ˆโ–ˆโ–ˆโ–ˆโ–ˆโ–ˆโ–ˆ โ–ˆโ–ˆโ–ˆโ–ˆโ–ˆโ–ˆโ–ˆโ–ˆ

โ—โ— companies
Description: โ–ˆโ–ˆโ–ˆโ–ˆโ–ˆโ–ˆโ–ˆโ–ˆ โ–ˆโ–ˆโ–ˆโ–ˆโ–ˆโ–ˆโ–ˆโ–ˆ โ–ˆโ–ˆโ–ˆโ–ˆโ–ˆโ–ˆโ–ˆโ–ˆ โ–ˆโ–ˆโ–ˆโ–ˆโ–ˆโ–ˆโ–ˆโ–ˆ โ–ˆโ–ˆโ–ˆโ–ˆโ–ˆโ–ˆโ–ˆโ–ˆ โ–ˆโ–ˆโ–ˆโ–ˆโ–ˆโ–ˆโ–ˆโ–ˆ โ–ˆโ–ˆโ–ˆโ–ˆโ–ˆโ–ˆโ–ˆโ–ˆ โ–ˆโ–ˆโ–ˆโ–ˆโ–ˆโ–ˆโ–ˆโ–ˆ โ–ˆโ–ˆโ–ˆโ–ˆโ–ˆโ–ˆโ–ˆโ–ˆ โ–ˆโ–ˆโ–ˆโ–ˆโ–ˆโ–ˆโ–ˆโ–ˆ
Key Products: โ–ˆโ–ˆโ–ˆโ–ˆโ–ˆโ–ˆโ–ˆโ–ˆ, โ–ˆโ–ˆโ–ˆโ–ˆโ–ˆโ–ˆโ–ˆโ–ˆ, โ–ˆโ–ˆโ–ˆโ–ˆโ–ˆโ–ˆโ–ˆโ–ˆ, โ–ˆโ–ˆโ–ˆโ–ˆโ–ˆโ–ˆโ–ˆโ–ˆ
๐Ÿ”’ View all companies in this group
Request Free Trial Now โ†’
๐Ÿ”’

Buyer group 3: โ–ˆโ–ˆโ–ˆโ–ˆโ–ˆโ–ˆโ–ˆโ–ˆ โ–ˆโ–ˆโ–ˆโ–ˆโ–ˆโ–ˆโ–ˆโ–ˆ

โ—โ— companies
Description: โ–ˆโ–ˆโ–ˆโ–ˆโ–ˆโ–ˆโ–ˆโ–ˆ โ–ˆโ–ˆโ–ˆโ–ˆโ–ˆโ–ˆโ–ˆโ–ˆ โ–ˆโ–ˆโ–ˆโ–ˆโ–ˆโ–ˆโ–ˆโ–ˆ โ–ˆโ–ˆโ–ˆโ–ˆโ–ˆโ–ˆโ–ˆโ–ˆ โ–ˆโ–ˆโ–ˆโ–ˆโ–ˆโ–ˆโ–ˆโ–ˆ โ–ˆโ–ˆโ–ˆโ–ˆโ–ˆโ–ˆโ–ˆโ–ˆ โ–ˆโ–ˆโ–ˆโ–ˆโ–ˆโ–ˆโ–ˆโ–ˆ โ–ˆโ–ˆโ–ˆโ–ˆโ–ˆโ–ˆโ–ˆโ–ˆ โ–ˆโ–ˆโ–ˆโ–ˆโ–ˆโ–ˆโ–ˆโ–ˆ โ–ˆโ–ˆโ–ˆโ–ˆโ–ˆโ–ˆโ–ˆโ–ˆ
Key Products: โ–ˆโ–ˆโ–ˆโ–ˆโ–ˆโ–ˆโ–ˆโ–ˆ, โ–ˆโ–ˆโ–ˆโ–ˆโ–ˆโ–ˆโ–ˆโ–ˆ, โ–ˆโ–ˆโ–ˆโ–ˆโ–ˆโ–ˆโ–ˆโ–ˆ, โ–ˆโ–ˆโ–ˆโ–ˆโ–ˆโ–ˆโ–ˆโ–ˆ
๐Ÿ”’ View all companies in this group
Request Free Trial Now โ†’
๐Ÿ”“ Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial โ†’

3. Investors and private equity firms

3.1 - Buyout funds investing in similar companies to Tharimmune

2.2 - Growth funds investing in similar companies to Tharimmune

๐Ÿ”’ View all growth equity funds with complete profiles
Start Free Trial โ†’

4 - Top valuation comps for Tharimmune

4.2 - Public trading comparable groups for Tharimmune

๐Ÿ”“ Unlock all public trading comparable groups with complete valuation data
Start Free Trial โ†’

4.3 - M&A Transactions similar to Tharimmune

Selected M&A transactions

Date Target Description Buyer(s) Relevance EV EV/Revenue EV/EBITDA
๐Ÿ”’ View all M&A transactions with complete deal terms
Request Free Trial Now โ†’

Frequently Asked Questions

About Tharimmune

What does Tharimmune do?

Tharimmune is a provider of development-stage therapeutics for cancer and chronic pruritus, including TH104, a transmucosal buccal film with nalmefene targeting ยต- and kappa-opioid receptors and inhibiting IL-17 for pruritus in PBC and other conditions; TH3215, a bispecific HER2/HER3 antibody; and TH1940, an anti-PD-1 Picobody therapy.

Who are Tharimmune's competitors?

Tharimmune's competitors and similar companies include Normunity, Cellerant Therapeutics, Mobidiag, GPC Biotech, and Synimmune.

Where is Tharimmune headquartered?

Tharimmune is headquartered in United Kingdom.

How many employees does Tharimmune have?

Tharimmune has 1,000 employees ๐Ÿ”’.

When was Tharimmune founded?

Tharimmune was founded in 2010 ๐Ÿ”’.

What sector and industry vertical is Tharimmune in?

Tharimmune is in the Enterprise Software ๐Ÿ”’ sector and industry

M&A Buyers & Acquirers for Tharimmune

Who are the top strategic acquirers in Tharimmune's sector and industry

Top strategic M&A buyers and acquirers in Tharimmune's sector include โ–ˆโ–ˆโ–ˆโ–ˆโ–ˆโ–ˆโ–ˆโ–ˆ, โ–ˆโ–ˆโ–ˆโ–ˆโ–ˆโ–ˆโ–ˆโ–ˆโ–ˆโ–ˆ, โ–ˆโ–ˆโ–ˆโ–ˆโ–ˆโ–ˆ, โ–ˆโ–ˆโ–ˆโ–ˆโ–ˆโ–ˆโ–ˆโ–ˆ, and โ–ˆโ–ˆโ–ˆโ–ˆโ–ˆโ–ˆโ–ˆโ–ˆโ–ˆโ–ˆ ๐Ÿ”’.

Which M&A buyer groups are most relevant for Tharimmune?

Top strategic M&A buyers groups and sectors for Tharimmune include โ–ˆโ–ˆโ–ˆโ–ˆโ–ˆโ–ˆโ–ˆโ–ˆโ–ˆโ–ˆโ–ˆโ–ˆโ–ˆโ–ˆโ–ˆโ–ˆโ–ˆ , โ–ˆโ–ˆโ–ˆโ–ˆโ–ˆโ–ˆโ–ˆโ–ˆโ–ˆโ–ˆโ–ˆโ–ˆโ–ˆโ–ˆโ–ˆโ–ˆ, โ–ˆโ–ˆโ–ˆโ–ˆโ–ˆโ–ˆโ–ˆโ–ˆโ–ˆโ–ˆโ–ˆโ–ˆโ–ˆ, โ–ˆโ–ˆโ–ˆโ–ˆโ–ˆโ–ˆโ–ˆโ–ˆโ–ˆโ–ˆโ–ˆโ–ˆ, and โ–ˆโ–ˆโ–ˆโ–ˆโ–ˆโ–ˆโ–ˆโ–ˆโ–ˆโ–ˆโ–ˆโ–ˆโ–ˆโ–ˆโ–ˆโ–ˆ ๐Ÿ”’.

Financial Investors investing in Tharimmune's sector and industry vertical

Which are the top PE firms investing in Tharimmune's sector and industry vertical?

Top PE firms investing in Tharimmune's sector and industry vertical include โ–ˆโ–ˆโ–ˆโ–ˆโ–ˆโ–ˆโ–ˆโ–ˆ, โ–ˆโ–ˆโ–ˆโ–ˆโ–ˆโ–ˆโ–ˆโ–ˆโ–ˆโ–ˆ, โ–ˆโ–ˆโ–ˆโ–ˆโ–ˆโ–ˆโ–ˆโ–ˆ, and โ–ˆโ–ˆโ–ˆโ–ˆโ–ˆโ–ˆโ–ˆโ–ˆโ–ˆโ–ˆ ๐Ÿ”’.

Who are the top buyout funds acquiring in Tharimmune's sector and industry vertical?

Active PE funds and buyout funds acquiring companies in Tharimmune's sector and industry vertical include โ–ˆโ–ˆโ–ˆโ–ˆโ–ˆโ–ˆโ–ˆโ–ˆโ–ˆ, โ–ˆโ–ˆโ–ˆโ–ˆโ–ˆโ–ˆโ–ˆโ–ˆโ–ˆโ–ˆ, โ–ˆโ–ˆโ–ˆโ–ˆโ–ˆโ–ˆโ–ˆโ–ˆโ–ˆโ–ˆโ–ˆโ–ˆ, and โ–ˆโ–ˆโ–ˆโ–ˆโ–ˆโ–ˆโ–ˆโ–ˆโ–ˆโ–ˆโ–ˆโ–ˆ ๐Ÿ”’.

Who are the top growth equity funds investing in companies in Tharimmune's sector and industry vertical?

Growth funds and venture capital funds investing in companies similar to Tharimmune include โ–ˆโ–ˆโ–ˆโ–ˆโ–ˆโ–ˆโ–ˆโ–ˆโ–ˆ, โ–ˆโ–ˆโ–ˆโ–ˆโ–ˆโ–ˆโ–ˆโ–ˆโ–ˆโ–ˆ, โ–ˆโ–ˆโ–ˆโ–ˆโ–ˆโ–ˆโ–ˆโ–ˆโ–ˆโ–ˆโ–ˆโ–ˆ, and โ–ˆโ–ˆโ–ˆโ–ˆโ–ˆโ–ˆโ–ˆโ–ˆโ–ˆโ–ˆโ–ˆโ–ˆ ๐Ÿ”’.

Valuation benchmarks of companies in Tharimmune's sector and industry

Which are the key public companies that are relevant trading comps benchmarks for Tharimmune?

The key public trading comparables and valuation benchmarks for Tharimmune include โ–ˆโ–ˆโ–ˆโ–ˆโ–ˆโ–ˆโ–ˆโ–ˆโ–ˆ, โ–ˆโ–ˆโ–ˆโ–ˆโ–ˆโ–ˆโ–ˆโ–ˆโ–ˆโ–ˆ, โ–ˆโ–ˆโ–ˆโ–ˆโ–ˆโ–ˆโ–ˆโ–ˆโ–ˆโ–ˆโ–ˆโ–ˆ, and โ–ˆโ–ˆโ–ˆโ–ˆโ–ˆโ–ˆโ–ˆโ–ˆโ–ˆโ–ˆโ–ˆโ–ˆ ๐Ÿ”’.

Which are the key trading comparable groups for Tharimmune for public valuation benchmarks?

Our platform tracks detailed public trading comparable groups and valuation benchmarks for Tharimmune with complete valuation multiples, growth metrics, and profitability data. Access the full database to benchmark your company against relevant public comparables.

What are recent M&A transactions in Tharimmune's sector and industry vertical?

Our platform tracks relevant M&A transactions comparables and valuation benchmarks for Tharimmune with complete deal terms, valuation multiples, and strategic rationale. Access the full database to benchmark pricing and identify active acquirers.

What are recent capital raises and funding rounds in Tharimmune's' sector and industry vertical?

Access recent funding rounds and capital raises in Tharimmune's sector and industry vertical including growth equity, venture capital, and buyout investments. Our database includes round size, lead investors and valuations.

Ready to Find the Right Buyers?

Access complete buyer lists, valuation data, and M&A intelligence for Tharimmune